Rwanda announces official timeline to begin use of Lenacapavir for HIV prevention

The medication, developed by U.S. based pharmaceutical company Gilead Sciences, will be administered once every six months, just two injections per year, offering a major alternative to existing HIV prevention options currently available in Rwanda, including daily oral pills and injections that provide protection for two months.

Speaking to The New Times, Dr. Zephanie Nzeyimana, working for the Rwanda Biomedical Centre, said preparations are underway to ensure health facilities meet all requirements before the rollout begins.

 “Lenacapavir will start being provided in Rwanda in the last quarter of this year. There are prerequisites that must be fulfilled before it is introduced in health facilities,” he said.

According to RBC, the injection will initially prioritize people at higher risk of HIV infection, including female sex workers, men who have sex with men, and HIV-negative partners in sero-discordant relationships.

However, Dr. Nzeyimana highlighted that access will not be limited to these groups alone, as health professionals will assess individual risk based on behavior and exposure.

Although Lenacapavir Yeztugo has been approved as safe for use, beneficiaries will receive counseling on appropriate behavior and will be required to report any unusual symptoms during treatment.

The drug will be provided free of charge, while related health services will continue to be covered under existing health insurance schemes, including community-based health insurance.

Several African countries, including Zambia, Zimbabwe, South Africa and Eswatini, have already approved Lenacapavir and are preparing to begin distribution after completing regulatory requirements and ordering initial supplies. Botswana, Malawi, Tanzania and Uganda have also approved the drug, while Kenya and Namibia are in the final stages of authorization.

RBC says the introduction of Lenacapavir Yeztugo marks a significant step in Rwanda’s broader strategy to reduce new HIV infections and expand access to innovative, user-friendly prevention methods.